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ABSTRACT
The McGill University Department of Oncology has
changed and expanded since its inception in 1990, re-
sponding to the move to interdisciplinary clinical care,
teaching, and research. Although the traditional Divi-
sions have been maintained to correspond to Univer-
sity and Royal College interfaces, the department has
steadily been generating a variety of cross-departmen-
tal and interdisciplinary programs in which new insights
into clinical care and biology are being generated. In
research areas ranging from psychosocial and funda-
mental to translational and clinical therapeutics,
interdisciplinarity and an emphasis on clinician–scien-
tists are critical features.
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1. HISTORICAL INTRODUCTION
The McGill University Department of Oncology was
founded in 1990 by then Dean of Medicine, Dr. Rich-
ard Creuss. It was the first such department in Canada,
having been made possible by a generous donation from
the Bronfman family in memory of Minda de
Gunzburg, daughter of Samuel and Saidye Bronfman
and wife of Baron Alain de Gunzburg. Dr. Brian
Leyland–Jones chaired the Department from 1990 to
2000 as the first Minda de Gunzberg Professor.
A second generous donation from Marjorie and
Gerald Bronfman allowed clinical research in oncol-
ogy at McGill to flourish, and in May 1992, the Gerald
Bronfman Centre for Clinical Research in Oncology
officially opened its doors. That building is currently
the home base for the Department of Oncology and
the location of the department’s administrative of-
fices. Other departmental programs currently
headquartered in the building include the centralized
Clinical Research Program, the Division of Cancer
Epidemiology, Cancer Genetics, the Cancer
Nutrition-Rehabilitation program, and the McGill Pro-
grams in Whole Person Care.
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Other endowments that were established in the
early days of the department include the Helen and
Sam Steinberg Family Career Award and the Flanders
Chair in Palliative Care.
The Department of Oncology was formed at a time
when, as nearly everywhere in Canada, clinical oncol-
ogy was largely invested in a department of radiation
therapy while medical oncology was either a subunit
of hematology or else a standalone division within a
department of medicine. The McGill Cancer Centre
(MCC), originally founded by Dean Samuel Freedman
under the directorship of Dr. Phil Gold, was a grouping
of affiliated research laboratories at the Medical Fac-
ulty Building. In time, the MCC developed a clinical
research program under the leadership of Dr. Richard
Margolese. With his great success in the National Sur-
gical Adjuvant Breast and Bowel Project, he joined
with other clinical leaders—Drs. Henry Shibata and
Lawrence Hutchison, among them—to generate suc-
cessful Cancer and Leukemia Group B funding and to
initiate participation in the National Cancer Institute
of Canada (NCIC) at a time when little investigator-
initiated clinical research was occurring.
The new Department of Oncology had a classical
divisional structure in which the erstwhile Department
of Radiation Oncology nobly accepted its role as a di-
vision within the department, the MCC became the Di-
vision of Basic Cancer Research, and MCC Clinical
Research was recognized as the new Division of Clini-
cal Oncology. To these were added the divisions of
Epidemiology and of Palliative Care. However, right
from the start, it was evident that modifications were
required. Within the first 18 months, “Clinical Trials
Operations” was established and a Pediatric Oncology
division was created, as was a transdivisional section
of Experimental Therapeutics, with the goal of gener-
ating a greater number of investigator-initiated trials.
Further changes followed, such that by 1995, the
Division of Clinical Oncology was split into the divi-
sions of Medical Oncology and of Surgical Oncology.
In addition, 13 trans-hospital multidisciplinary research
sections were created to develop, review, and oversee
clinical research activities for various tumour types—
for example, leukemia, lymphoma, melanoma, neuro-
oncology, endocrine/biologics, breast cancer, and so on.MCGILL UNIVERSITY DEPARTMENT OF ONCOLOGY
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The department encompassed research and training at
the Montreal General Hospital, The Royal Victoria
Hospital, St. Mary’s Hospital, and the Sir Mortimer B.
Davis–Jewish General Hospital. In addition to Clini-
cal Trials Operations at the Gerald Bronfman Centre,
the early 1990s saw the creation of the Clinical Re-
search Unit at the Sir Mortimer B. Davis–Jewish Gen-
eral Hospital, the focal point for phase I and complex
phase II clinical trials.
As clinical care and research in oncology were
being structured and expanded, the department also
gave top priority to oncology teaching and training. By
the mid-1990s, a Medical Education Committee to
address undergraduate education and four oncology
residency training programs (medical, radiation, sur-
gical, and hematologic oncology) were established.
Furthermore, a new lecture series, the bi-annual Ce-
dars Visiting Professorships was created in the early
1990s to supplement Oncology Grand Rounds. Over
the years, that lecture series changed and evolved to
become the Visiting Speakers in Oncology program.
The latter program, a joint effort with the Université
de Montréal, sponsors approximately 20 visiting pro-
fessors annually.
2. ONCOLOGY IN THE NEW MILLENNIUM:
INTERDISCIPLINARY TEAM-BUILDING
Starting in the late 1990s, it became increasingly clear
that a much closer link was essential between scien-
tists and health care professionals in all fields to capi-
talize on scientific advances in cancer control. Not
only is new knowledge required, but also the ability to
translate biologic knowledge into clinically relevant
questions or even therapies, and then to transfer new
clinical knowledge to caregivers, the public, and health
policymakers. Optimal conditions for everything from
the development of innovative therapies to the training
and continuing education of professionals requires an
intimate linking of efforts from various medical disci-
plines—and ultimately from various health care pro-
fessions. Furthermore, the University has recently
been called on to play a larger role in the planning
and delivery of health care outside of its traditional
institutional boundaries.
2.1 Réseau universitaire intégré de santé
Quebec has established a novel structure of health care
based on the four university-based health networks
(McGill University, Université de Montréal, Université
de Sherbrooke, and Université de Laval), each one
servicing a particular geographic region and responsi-
ble for the coordination of health care services, research,
and teaching in its area. The McGill Department of
Oncology is the central hub for coordinating oncology
care, research, and education within the McGill Réseau
universitaire intégré de santé (RUIS) region, and it plays
a critical role in integrating those activities within the
McGill-affiliated institutions [McGill University
Health Centre (MUHC), Segal Cancer Centre–Sir
Mortimer B. Davis–Jewish General Hospital, St.
Mary’s Hospital Centre]. The “table d’oncologie,” a
committee of representatives from all of the forego-
ing institutions and of various disciplines of cancer
care, plus epidemiologists, health care administrators,
pharmacists, and patient representatives, is the coor-
dinating body for the department.
The table d’oncologie meets monthly and imple-
ments programs of outreach to remote communities,
video and telephone consultations, rapid inter-institu-
tional referrals, practice guidelines, and policies. A
guiding principle is ready access to the standard of prac-
tice as close to home as possible. Research collabora-
tions are also developing between the university centres
and the regional authorities. For example, evidence
accumulated by the Abitibi–Témiscamingue public
health authorities showed that some water and soil may
contain significantly elevated levels of arsenic, undoubt-
edly related to the region’s history of mining. As it hap-
pens, Dr. Koren Mann at the Segal Cancer Centre has a
developing interest and expertise in the environmental
aspects of arsenic and is investigating this problem in
areas of the U.S. Southwest, just as her associate Dr.
Wilson Miller is an authority on arsenic’s emerging use
as a cancer therapeutic. Such obvious opportunities for
research programs that engage university-based scien-
tists with remote regions are being exploited by the RUIS
relationship.
2.2 Interdisciplinary Programs
In response to the evolving nature of the relationship
between fundamental knowledge discovery and trans-
lational research, and subsequent knowledge transfer
into clinical practice (where population-based studies
are then employed), the McGill Department of Oncol-
ogy has changed its shape and internal configuration.
The aim is to further the goal of an integrated approach
to cancer care, research, and education by creating a
number of interdisciplinary programs that transcend
disease sites and specific tumour types, concentrating
instead on specific areas of research and treatment
(Figure 1). The classical divisions remain, mostly to
provide a context for the various training programs and
to interface with professional organizations that are
based on subspecialties, but the activities of the mem-
bers of each of the interdisciplinary groupings have
clearly breached the classical division boundaries.
For example, each of the McGill-affiliated hospi-
tals has a team of medical oncologists, some of whom
provide services at more than one hospital, and many
of whom regularly link by videoconference for various
meetings to facilitate networking and sharing of ideas.
In addition to being on the front line in diagnosing and
treating cancer patients, some of the medical
oncologists are also involved in other aspects of cancer
care such as screening, prevention, rehabilitation,BATIST and SHINDER
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symptom management, and palliative care. The
medical oncologists work in interdisciplinary teams
with surgical and radiation oncologists, nurses, and
oncology pharmacists to provide the best possible care
for their patients. They also are actively involved in
many clinical studies, thus giving their patients ac-
cess to the most recent advances in cancer therapy. A
number of the medical oncologists also have produc-
tive and well-funded fundamental and translational
research programs.
Similar developments have also occurred in
hematology–oncology and in surgical oncology, where
research programs such proteomic and genomic ar-
ray technologies for biomarker discovery and vali-
dation, conducted by clinician–scientist Dr. Mark
Basik, clearly blur the distinction between disciplines.
The Division of Radiation Oncology, directed by Dr.
Carolyn Freeman, is already multidisciplinary, com-
prising physicians, physicists, and radiation scientists.
That division is well known for its technology develop-
ment and clinical application of innovations in
medical physics. Dr. Ervin Podgorsak has been a
remarkable innovator, providing the groundwork for
a variety of therapeutic approaches in a range of tu-
mour types from brain irradiation to endo-rectal high
dose rate brachytherapy.
For the most part, however, the current structure
of the department reflects the multi- and interdiscipli-
nary nature of both clinical practice and scientific in-
quiry that is the emerging model. In fact, it reflects
that model to the point that the department’s training
program has been highlighted by the creation of an
Interdisciplinary Training Committee designed to fos-
ter inter-professional interactions among the clinical
trainees as preparation and prelude to the careers that
they face in the near future. The Division of Cancer
Epidemiology (Dr. Eduardo Franco) played a key role
through a regular journal club attended by the trainees
from all disciplines.
An innovative example of transcending departmen-
tal structure was the development and recent university
approval of the Psychosocial Oncology Option, which
is coordinated through the Department of Oncology and
forges links between faculty and students in the Depart-
ments of Oncology and Psychology and in the Schools
of Nursing and Social Work. The Psychosocial Oncology
FIGURE 1    Department of Oncology, McGill University.MCGILL UNIVERSITY DEPARTMENT OF ONCOLOGY
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Option is further discussed under the Psychosocial On-
cology Program later in this article.
2.2.1 Division of Cancer Epidemiology
A generous endowment to McGill in 1988 by the Can-
cer Research Society resulted in the establishment of
the Division of Cancer Epidemiology. Although prima-
rily a unit within the Department of Oncology, Cancer
Epidemiology, which is directed by Dr. Eduardo Franco,
is also part of the McGill Department of Epidemiol-
ogy and Biostatistics. The program conducts epidemio-
logic research on the causes and prognosis of cancers,
with the aim of providing recommendations for pre-
vention strategies. Its main foci are cervical cancer,
upper aero-digestive tract tumours, and childhood ma-
lignancies. Its research program in cervical cancer has
examined the natural history of cervical cancer, pre-
cursor lesions, and also risk determinants such as in-
fection with the human papillomavirus (HPV).
Researchers in the program have also investigated the
epidemiology of environmental and social determi-
nants of upper aero-digestive tract cancer and child-
hood cancers.
In the area of cancer prevention, researchers in
Cancer Epidemiology have also been developing math-
ematical models to assess the cost-effectiveness of
cancer prevention strategies in Canada and internation-
ally. That research has been carried out internationally
with studies and collaborations in Brazil, the Republic
of Congo, and Lyon, France (with the International
Agency for Research on Cancer).
Cancer Epidemiology also offers its expertise in
statistical and study planning to other researchers in
the Department of Oncology, and it has an active teach-
ing program for undergraduate and graduate students
and postdoctoral and medical fellows.
2.2.2 Division of Palliative Care
The Division of Palliative Care, directed by Dr. Anna
Towers, includes members from the various McGill-
affiliated institutions. The Division not only provides
clinical care to adult cancer patients in the final stages
of their disease, but also to pediatric palliative care
patients through specially trained physicians based at
the Montreal Children’s Hospital. Palliative Care Re-
search, directed by Dr. Robin Cohen, is an important
component of the Division and many of its members
conduct research programs in areas such as pain con-
trol, lymphedema, anorexia–cachexia, and quality of
life. Dr. Cohen also directs the Canadian Institutes of
Health Research (CIHR)/NCIC Strategic Training Pro-
gram in Palliative Care, which is a collaborative train-
ing program involving McGill, Université de Laval,
and the University of Ottawa. Consistent with the gen-
eral move toward integration and transcendence of dis-
ciplinary barriers, Dr. Bernard Lapointe’s Palliative
Care Program at the Jewish General Hospital was des-
ignated an “integrated program” in 2007, the first North
American site to be so designated by the European
Society of Medical Oncology. Dr. Lapointe’s vision has
moved palliative care into the “supportive care” realm,
focusing not only on end-of-life care, but also on symp-
tom management, both medical and psychosocial, of
curable patients early in their disease trajectory. This
expansion of the boundaries of the discipline has been
taken up by other McGill palliative care doctors, in-
cluding Drs. Neil MacDonald and Martin Chasen, who
work on the nutritional and rehabilitation aspects. Some
of Dr. Cohen’s research even departs from direct con-
tact with the patient to focus on family caregivers, a
move that is strikingly insightful and responsive to a
real need in today’s society.
2.2.3  Other Interdisciplinary Programs
The McGill Head and Neck Cancer Program   Directed by
Dr. Martin Black, this group functions in two hospi-
tals, handling high-quality care, clinical research, and
teaching. Research activities include novel therapeu-
tics and tumour biomarkers (Dr. Moulay Alaoui–
Jamali). The group also has a strong link to the McGill
School of Dentistry, where Dr. Paul Allison leads a
large program that touches on public and oral health,
and the psychosocial aspects of head and neck cancer.
In addition, Dr. Franco has generated a significant re-
search program based initially on the role of HPV virus
in nasopharyngeal cancer.
The McGill Pediatric Oncology Program   Centred at the
Montreal Children’s Hospital, the Pediatric Oncology
Program provides care for cancer patients 0–18 years
of age. The hospital’s pediatric neuro-oncology pro-
gram, with its interdisciplinary team that includes 3
skilled pediatric neurosurgeons, sees 65% of pediatric
brain tumours in Quebec. Dr. Nada Jabado is a clini-
cian–scientist with a major translational research pro-
gram in brain tumours. The Montreal Children’s
Hospital is also the focal point for the Quebec retino-
blastoma program, collaborating with staff from
Hôpital Ste. Justine. Most of the services necessary
for care provision are available on site, but the pediatric
oncology team at the Montreal Children’s Hospital also
works collaboratively with the adult hospitals to pro-
vide services such as radiotherapy, some laboratory
tests, a long-term follow-up clinic, and the Adolescent
and Young Adult Oncology Program.
The McGill Pediatric Oncology Program is actively
involved in clinical research as a full member of the
Children’s Oncology Group, and provides training to
postgraduates and fellows enrolled in the general sur-
gery, neurosurgery, and radiation oncology programs.
The Adolescent and Young Adult Oncology Program   Caught
between childhood and adulthood, adolescents and
young adults with cancer must not only contend with
the unique challenges of their stage in life, but also
with the cancer experience itself. Established in early
2003 under the leadership of Dr. Petr Kavan, theBATIST and SHINDER
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Adolescent and Young Adult Oncology Program deals
with the different types of cancers that occur in young
adults as compared with adults, and that tend not to
respond as well to adult treatment protocols. The goals
of the program are to provide optimal interdisciplinary
care for this unique population; to involve the patient
population more actively in national and international
multicentre research protocols and projects, and in in-
house protocols; to improve the access of this popula-
tion to psychosocial support services (social services,
psychologists, psychiatrists); and to improve teaching
about and research into the challenges faced by ado-
lescent and young adult cancer patients.
The Cancer Prevention Program   Under the direction of
Dr. Michael Pollak, the Cancer Prevention Program
(www.mcgill.ca/cancerprev) was inaugurated in Oc-
tober 2002. It includes an academic research program
and clinical and educational programs designed to make
the public aware of cancer prevention. Clinical pro-
grams are based at the Stroll Family Cancer Preven-
tion Centre at the Segal Cancer Centre of the Sir
Mortimer B. Davis–Jewish General Hospital. The
Centre offers programs in smoking cessation, diet, and
lifestyle, and also coordinates the activities at the Segal
Cancer Centre of the cancer geneticists who work with
people concerned about the possibility of genetic pre-
disposition to cancer in their family. The Cancer Pre-
vention Program’s research component comprises an
interdisciplinary group of researchers and clinical spe-
cialists who conduct laboratory and epidemiologic re-
search projects aimed at improving the understanding
of cancer risk and ultimately preventing cancer. Mem-
bers of the program team deliver lectures to under-
graduates and medical students and provide
opportunities for medical students to carry out electives
in cancer prevention. In addition, members of the team
provide research projects for graduate students and
postdoctoral fellows interested in cancer risk and can-
cer prevention.
McGill Program in Cancer Genetics   The Cancer Genet-
ics Program (www.mcgill.ca/cancergenetics), under the
direction of Dr. William Foulkes, was established as a
joint program of the departments of Oncology and of
Human Genetics. The goal was to establish, in Mon-
treal, a leading interdisciplinary centre for hereditary
cancer genetics that is an ideal context for clinical serv-
ice, research, and teaching. Together with colleagues
in Pathology at the Sir Mortimer B. Davis–Jewish Gen-
eral Hospital, the Program in Cancer Genetics is ac-
tive in several areas of hereditary cancer, in particular
hereditary breast and ovarian cancer caused by muta-
tions in BRCA1 and BRCA2, and hereditary colorectal
cancer. In the past year, Dr. Marc Tischkowitz and col-
leagues have focused on determining the contribution of
a new breast cancer gene, PALB2, to the incidence of
breast cancer in Quebec. Dr. Foulkes and colleagues
identified and characterized a novel mutation in PMS2
(a hereditary colorectal cancer gene) that is present in
at least two families of Inuit origin from Nunavik
(unpublished data). The identification of the same mu-
tation in two unrelated families could have conse-
quences for screening in that remote population.
Substantial work has also been carried out by Dr.
Patricia Tonin with respect to ovarian cancer
pathogenesis. Recently, Dr. Raquel Aloyz and col-
leagues have begun to look at cell line models of can-
cer and how new drugs may be effective against
hereditary forms of breast cancer (unpublished data).
In terms of international visibility, the Program hosted,
in collaboration with the Hereditary Breast and Ovar-
ian Cancer Foundation (www.hboc.ca), the Second
International Symposium on Hereditary Breast and
Ovarian Cancer, Montreal, October 17–19, 2007. More
than 250 attendees listened to 30 international, national,
provincial, and local researchers present a comprehen-
sive overview of hereditary breast and ovarian cancer,
from the base pairs altered in individuals at risk to the
psychological dimension of being a gene carrier.
The McGill Cancer Nutrition-Rehabilitation Program   The
McGill Cancer Nutrition-Rehabilitation (CNR) Program
(www.mcgill.ca/cnr), whose founding director is Dr.
Neil MacDonald, was instituted in 2002 to treat can-
cer patients experiencing poor appetite, malnutrition,
weight loss, fatigue, and loss of function. The Program
has two clinic sites, one at the Segal Cancer Centre of
the Sir Mortimer B. Davis–Jewish General Hospital
(Medical Director: Dr. MacDonald) and one at the
MUHC–Royal Victoria Hospital (Medical Director: Dr.
Martin Chasen). The administrative office is housed
at the Gerald Bronfman Centre at McGill.
The mission of the McGill CNR Program, which
encompasses clinical care, research, and education, is
to develop and administer nutritional, rehabilitation, and
psychosocial programs for cancer patients who are
suffering from poor appetite, malnutrition, weight loss,
fatigue, loss of function, and psychological distress; to
conduct research aimed at understanding the underly-
ing biologic reasons that patients with cancer suffer
from the foregoing symptoms; to educate patients, fam-
ily caregivers, and health professionals in new ways to
manage those symptoms; to take part in national and
international study groups that investigate new medi-
cal treatments and other therapies, and to enrol pro-
gram patients into ethically approved trials; to
investigate and provide for the needs of patients who
are “cancer survivors”; and to act as a referral and
reference centre for patients and professionals.
The dedicated team of professionals in the pro-
gram include physicians specializing in cancer nutri-
tion, rehabilitation, anticancer therapies, and symptom
control; nurses who are experienced in providing health
care, education, and support to cancer patients and their
families; physiotherapists who can design individual-
ized exercise programs for patients to improve their
physical performance and stamina; dietitians whoseMCGILL UNIVERSITY DEPARTMENT OF ONCOLOGY
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chief aims are to enhance and optimize the nutritional
intake of patients, allowing for optimal weight;
occupational therapists who specialize in functional
assessment and implementation of activity-directed re-
habilitative programs, thus aiding patients to function
optimally in the activities of daily life; and a psycholo-
gist with experience working with patients throughout
the illness trajectory. In October 2007, Dr. Thomas
Jagoe, a pulmonologist whose research interests in-
clude mechanisms of muscle wasting, particularly in
cancer, joined the group as Program Director.
The Psychosocial Oncology Program   The Psychosocial
Oncology Program was initially a joint venture of the
McGill departments of Oncology and of Psychiatry.
The program is currently directed by Dr. Zeev
Rosberger and incorporates clinical psychology, psy-
chiatry, nursing, palliative care, and quality of life re-
search. The main goals of the program are to develop
research capacity and enhance recruitment of psycho-
social oncology researchers; to train and supervise
graduate students; and to develop a teaching program
in psychosocial oncology research. To further the lat-
ter goal, the Department of Oncology has forged links
with the Department of Psychology, the School of Nurs-
ing, and the School of Social Work to initiate a new
program option called the Psychosocial Oncology Op-
tion. Doctoral students in the School of Nursing and
the Department of Psychology who are interested in
psychosocial oncology can take this program option.
Students are required to take Psychosocial Oncology
Research, a course given by the School of Nursing’s
Dr. Carmen Loiselle, who is an Associate Member of
the Department of Oncology, and the course Palliative
Care in Cancer given by Dr. Cohen from the Depart-
ment of Oncology. In addition, they are required to
choose one of five complementary courses given by
the Department of Psychology or the School of Social
Work. This program option provides an excellent op-
portunity for participating students and academic staff
in various disciplines to join forces and generate new
psychosocial oncology knowledge that may ultimately
be used in clinical settings.
Nursing Oncology   The Department of Oncology rec-
ognizes the central role that nursing plays in cancer care
and has worked closely with the School of Nursing and
an established group of academic nurses whose re-
search interests focus on oncology nursing. The clini-
cal research programs are aimed at providing a better
understanding of the psychosocial issues faced by can-
cer patients and their families, including emotional
stress, decision-making, and information-seeking strat-
egies. Dr. Carmen Loiselle is the director of the pro-
gram and links it with nursing colleagues throughout
McGill and beyond. The recent introduction of “nurse
navigators in oncology” (“infirmières pivots en
oncologie”) in Quebec provides an important opportu-
nity for Dr. Loiselle and her colleagues to critically
evaluate various models for this role.
In 2003, the Psychosocial Oncology Research
Training program was created as a result of a Strate-
gic Training Grant awarded to Dr. Loiselle and her
colleagues by the CIHR–Institute of Cancer Research
and NCIC. The program comprises a multidisciplinary
team of researchers (nursing, psychology, manage-
ment, and medicine) from McGill University, the Uni-
versity of Manitoba, the University of British Columbia,
and Dalhousie University, and was designed to pro-
vide graduate-level fellowships and awards so that
young researchers can learn to develop, test, and re-
fine psychosocial cancer care interventions that are
effective, accessible, and beneficial for people deal-
ing with a cancer diagnosis.
The McGill Programs in Whole Person Care   The McGill
Programs in Whole Person Care, under the direction
of Dr. Thomas Hutchinson (as of 2004), were insti-
tuted in February 1999 on the initiative of Drs. Balfour
Mount and Abraham Fuks (the latter being Dean of
Medicine at the time). The goal of the programs is to
better understand how to respond to suffering experi-
enced by the whole person by incorporating the physi-
cal, psychosocial, and existential/spiritual aspects of
the person. The idea behind this approach is to allow
for healing in situations in which treatment is unlikely
to change the outcome of the disease.
Research programs use qualitative methodology to
focus on determinants of healing and whole-person
care. Members of the multidisciplinary team have ex-
pertise in qualitative methodology, mindfulness-based
stress reduction, end-stage renal disease, palliative
care, and healing. Members teach undergraduate- and
graduate-level courses and are responsible for the heal-
ing component of the Physicianship Program in the
Faculty of Medicine. Two public education programs
are also offered on a monthly basis:
￿ Invited speakers give presentations at the lunch-
time series McGill Seminars in Healing
￿ The series Films That Transform uses film and
follow-up dialogue with the series discussants to
help the audience achieve a better understanding
of healing in a biomedical context
The Community Cancer Care Program   Under the direc-
tion of Dr. Jaroslav Prchal at St. Mary’s Hospital Cen-
tre, the mandate of the Community Cancer Care
Program is to encourage the development of cancer
care in community hospitals so that patients can be
treated as close to their living environment as possi-
ble. To provide the best service to the ever-growing
numbers of cancer patients and cancer survivors, rais-
ing the number of physicians trained in cancer care is
of utmost importance. To achieve that goal, the Com-
munity Cancer Care Program plans to provide spe-
cific training sessions to general practitioners and
family practitioners and to provide increased cancerBATIST and SHINDER
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treatment education at the undergraduate and post-
graduate levels.
2.3 Cancer Research
2.3.1 McGill Cancer Centre
The MCC, established in 1978, is the core of basic can-
cer research at McGill, co-ordinating cancer research
activities within various McGill departments and af-
filiated hospitals. Under the direction of Dr. Michel
Tremblay, the MCC’s research activities focus on a
wide range of topics such as signal transduction, dif-
ferentiation, cell proliferation, gene therapy, radiation
resistance, and drug development. The MCC has re-
cently linked with the Molecular Oncology Group,
which until recently was based at the Royal Victoria
Hospital. It was established in 1994 as an independ-
ent research division within the Department of Medi-
cine and is internationally renowned for its work on
cellular and molecular biology of cancer. The group,
headed by Dr. Morag Park, comprises six laboratories
whose research programs focus on the molecular con-
trol of cell growth and differentiation and the effect of
changes at the genomic or proteomic level on tumour
initiation and progression. Collaborations with medical
and surgical oncologists, pathologists, and pharmaceu-
tical and biotechnology companies facilitate the trans-
lation of research findings into therapeutic strategies
and drug development.
2.3.2 McGill Centre for Translational Research in
Cancer/Montreal Centre for Experimental
Therapeutics in Cancer
The Montreal Centre for Experimental Therapeutics
in Cancer (MCETC) was established in 2000 as a result
of a Canada Foundation for Innovation (CFI)/Fonds de
la recherche en santé du Québec (FRSQ) infrastructure
award to the McGill Centre for Translational Research
in Cancer (MCTRC) for the construction of a state-of-
the-art laboratory that would provide a link between
basic and clinical research. With the addition of ma-
jor infrastructure funding from Quebec and the suc-
cessful recruitment of new members to the Centre,
the facility that was built is twice as large as origi-
nally planned. The new facility, which was up and
running by October 2005, occupies the fourth and fifth
floors (more than 3700 m2) of the newly built E-wing
expansion at the Sir Mortimer B. Davis–Jewish Gen-
eral Hospital. It is closely linked with the Segal Can-
cer Centre on the seventh through ninth floors of the
expanded E-wing.
The MCTRC/MCETC has research programs cov-
ering four main themes: drug target discovery and vali-
dation, new drug development, cell and gene therapy,
and prevention and risk assessment. The Centre also
provides eight core facilities: a clinical research unit,
cell preparation centre, DNA and tissue bank, viral
vector production unit, flow cytometry unit, high-
performance computational biology and drug
development unit, peptide synthesis laboratory, and re-
search pathology core facility. The centre, with its high
throughput system of both preclinical and early-phase
clinical trials, has made major contributions to the de-
velopment of novel therapies.
In addition to the research being performed at the
newly built facility, the MCTRC/MCETC team also in-
cludes researchers at four other universities—the
Université de Montréal, Université du Québec à
Montréal, Université de Laval, and Université de
Sherbrooke—and six hospital-based or independent
research institutes—Lady Davis Institute for Medical
Research, the Institut national de recherche
scientifique–Institut Armand Frappier, Ste. Justine
Hospital Research Centre, Biotechnology Research
Institute of the National Research Council, Centre de
recherche clinique et évaluative en oncologie du Cen-
tre hospitalier universitaire de Québec (CRCEO-CHUQ),
and Centre hospitalier universitaire de Sherbrooke.
2.3.3 Clinical Research
The Clinical Research Program in the Department of
Oncology is co-directed by Drs. Wilson Miller from
the Sir Mortimer B. Davis–Jewish General Hospital
and Catalin Mihalcioiu from the MUHC–Montreal
General Hospital. The program oversees phase I, II,
and III oncology clinical trials (sponsored by NCIC, the
Radiation Therapy Oncology Group, pharmaceutical and
biotechnology companies) and investigator-initiated stud-
ies that are conducted at McGill-affiliated hospitals.
The Clinical Research Unit of the Sir Mortimer
B. Davis–Jewish General Hospital, which was es-
tablished as the first of its kind in Quebec in 1993,
moved in early 2006 to its new location on the eighth
floor of the Segal Cancer Centre. The unit is directed
by Dr. Miller and conducts phase I and early phase II
oncology clinical trials with a strong focus on
hematologic oncology. The treatment area includes
four beds, three chemotherapy treatment chairs, and
an additional single patient room. Patients come not
only from McGill-affiliated hospitals, but also from
hospitals throughout Quebec. The Unit is an integral
part of the Montreal Centre for Experimental Thera-
peutics in Cancer and its goal to bring cancer research
from the laboratory bench to the clinic.
3. FUTURE DIRECTIONS
3.1 New Program
Ever-alert for joint ventures that cross disciplinary lines,
the Department of Oncology has launched a project to
develop a Cancer Pathology Program that will link its
work with that of the Department of Pathology. The
emerging central role of molecular pathology, both for
research and for individualized clinical care, makes
that link imperative.MCGILL UNIVERSITY DEPARTMENT OF ONCOLOGY
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3.2 Networking Across Quebec
The two CFI-sponsored cancer centres in Quebec, the
Segal Cancer Centre at the Jewish General Hospital
and the Centre de recherche clinique et évaluative en
oncologie (CRCEO) of the Hôtel-Dieu du Québec (Di-
rector: Dr. Luc Bélanger) have enjoyed a natural link
since they cross-referenced one another in their original
applications, and they since have shared major fund-
ing. Together, they are the experimental therapeutics
axis of the FRSQ’s Cancer Research Network
(Directrice: Dr. Anne-Marie Mes–Masson). They have
now linked to form the Quebec Clinical Research Or-
ganization in Cancer, whose initial major program is
profiling clinical resistance. The program garnered the
active participation of major clinical scientists and ba-
sic researchers from McGill, Université de Montréal,
Université de Sherbrooke, and Université de Laval. The
hope is that this collaboration will bring energy and struc-
ture to an evolving clinical and translational research
network in Quebec.
4. SUMMARY
As knowledge becomes both more complex and more
useable, it necessarily crosses established disciplinary
and university departmental boundaries. This boundary
crossing has resulted in novel insights and remarkable
synergies. The associated change is not easy; it re-
quires a rethink of many of the structures upon which
budgets and career planning have generally been made.
Yet it is an irresistible movement that the McGill De-
partment of Oncology has tried to join and to incorpo-
rate into its development. It includes delivery of health
care, research, and teaching. The training aspect is
most important, because the rate of change is so rapid
that continuous revisions and rethinking are required.
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